Scotiabank Maintains Sector Perform on Biomarin Pharmaceutical, Raises Price Target to $95
Portfolio Pulse from Benzinga Newsdesk
Scotiabank analyst George Farmer maintains a Sector Perform rating on Biomarin Pharmaceutical and raises the price target from $86 to $95.
September 05, 2024 | 3:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scotiabank analyst George Farmer has maintained a Sector Perform rating on Biomarin Pharmaceutical and increased the price target from $86 to $95, indicating a positive outlook.
The increase in the price target from $86 to $95 by Scotiabank suggests a positive outlook for Biomarin Pharmaceutical, which could lead to a short-term increase in stock price. The maintained Sector Perform rating indicates steady performance expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100